Literature DB >> 30679330

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.

Laurence C Cheung1,2, Mark N Cruickshank1, Anastasia M Hughes1, Sajla Singh1, Grace-Alyssa Chua1, Jette Ford1, Emanuela Ferrari1, Joyce Oommen1, Sébastien Malinge1, Richard B Lock3, Ursula R Kees1, Rishi S Kotecha4,2,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30679330      PMCID： PMC6601077          DOI： 10.3324/haematol.2018.192906

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.

Authors:  M Waibel; S J Vervoort; I Y Kong; S Heinzel; K M Ramsbottom; B P Martin; E D Hawkins; R W Johnstone
Journal:  Leukemia       Date:  2017-09-15       Impact factor: 11.528

2.  The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.

Authors:  P Garrido Castro; E H J van Roon; S S Pinhanços; L Trentin; P Schneider; M Kerstjens; G Te Kronnie; O Heidenreich; R Pieters; R W Stam
Journal:  Leukemia       Date:  2017-07-10       Impact factor: 11.528

3.  The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

Authors:  A M Savino; J Sarno; L Trentin; M Vieri; G Fazio; M Bardini; C Bugarin; G Fossati; K L Davis; G Gaipa; S Izraeli; L H Meyer; G P Nolan; A Biondi; G Te Kronnie; C Palmi; G Cazzaniga
Journal:  Leukemia       Date:  2017-03-23       Impact factor: 11.528

4.  Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.

Authors:  Jennifer Richmond; Hernan Carol; Kathryn Evans; Laura High; Agnes Mendomo; Alissa Robbins; Claus Meyer; Nicola C Venn; Rolf Marschalek; Michelle Henderson; Rosemary Sutton; Raushan T Kurmasheva; Ursula R Kees; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2015-01-08       Impact factor: 12.531

Review 5.  MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.

Authors:  Amanda C Winters; Kathrin M Bernt
Journal:  Front Pediatr       Date:  2017-02-09       Impact factor: 3.418

6.  Late effects in survivors of infantile acute leukemia: a study of the L.E.A program.

Authors:  V Gandemer; J Bonneau; C Oudin; J Berbis; Y Bertrand; M-D Tabone; S Ducassou; P Chastagner; B Brethon; J-H Dalle; S Thouvenin; M Poiree; D Plantaz; J Kanold; N Sirvent; P Lutz; Z Hamidou; A Baruchel; G Leverger; P Auquier; G Michel
Journal:  Blood Cancer J       Date:  2017-01-20       Impact factor: 11.037

7.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

Authors:  Rob Pieters; Martin Schrappe; Paola De Lorenzo; Ian Hann; Giulio De Rossi; Maria Felice; Liisa Hovi; Thierry LeBlanc; Tomasz Szczepanski; Alice Ferster; Gritta Janka; Jeffrey Rubnitz; Lewis Silverman; Jan Stary; Myriam Campbell; Chi-Kong Li; Georg Mann; Ram Suppiah; Andrea Biondi; Ajay Vora; Maria Grazia Valsecchi
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

8.  The evolution of clinical trials for infant acute lymphoblastic leukemia.

Authors:  R S Kotecha; N G Gottardo; U R Kees; C H Cole
Journal:  Blood Cancer J       Date:  2014-04-11       Impact factor: 11.037

Review 9.  Use of class I histone deacetylase inhibitor romidepsin in combination regimens.

Authors:  Adam Petrich; Chadi Nabhan
Journal:  Leuk Lymphoma       Date:  2016-04-27

10.  Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.

Authors:  M N Cruickshank; J Ford; L C Cheung; J Heng; S Singh; J Wells; T W Failes; G M Arndt; N Smithers; R K Prinjha; D Anderson; K W Carter; A M Gout; T Lassmann; J O'Reilly; C H Cole; R S Kotecha; U R Kees
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528
  10 in total
  1 in total

1.  Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia.

Authors:  Laurence C Cheung; Rebecca de Kraa; Joyce Oommen; Grace-Alyssa Chua; Sajla Singh; Anastasia M Hughes; Emanuela Ferrari; Jette Ford; Sung K Chiu; Ronald W Stam; Ursula R Kees; Sébastien Malinge; Rishi S Kotecha
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.